Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks postpartum: Results of the ban study

Antiviral Therapy

Volumn 19, Issue 6, 2014, Pages 587-595

  Corbett, Amanda H ^a   Kayira, Dumbani ^b   White, Nicole R ^f   Davis, Nicole L ^c   Kourtis, Athena P ^f   Chasela, Charles ^b   Martinson, Francis ^b   Phiri, Grace ^b   Musisi, Bonaface ^f   Kamwendo, Deborah ^b   Hudgens, Michael G ^c   Hosseinipour, Mina C ^b,e   Nelson, Julie A E ^e   Ellington, Sascha R ^d   Jamieson, Denise J ^d   Van Horst, Charles Der ^e   Kashuba, Angela ^a  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^c IL   (United States)

^d NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BREAST FEEDING; BREAST MILK; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MILK LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC50; INFANT; LIMIT OF DETECTION; MATERNAL AGE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PREGNANCY DISORDER; PRENATAL DRUG EXPOSURE; PROSPECTIVE STUDY; PROTEIN BINDING; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD; VIRUS RESISTANCE; CLINICAL TRIAL; DRUG MONITORING; HIV INFECTIONS; MALE; MOTHER; TIME; VIROLOGY; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; MILK, HUMAN; MOTHERS; TIME FACTORS; VIRAL LOAD; YOUNG ADULT;

EID: 84904608995     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2739     Document Type: Article

References (32)

1. Nduati R, Richardson BA, John G, et al. Effect of breastfeeding on mortality among HIV-1 infected women: a randomised trial. Lancet 2001; 357:1651-1655.
2. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana. A randomized trial: the Mashi Study. JAMA 2006; 296:794-805.
3. UNAIDS. Global report. UNAIDS report on the global AIDS epidemic 2013. (Updated November 2013. Accessed 19 September 2014.) Available from http://www.unaids.org/en/ media/unaids/contentassets/documents/epidemiology/2013/ gr2013/UNAIDS-Global-Report-2013-en.pdf
4. Week Extended-Dose Nevirapine (SWEN) Study Team. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008; 372:300-313.
5. Jamieson DJ, Chasela CS, Hudgens MG, et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised, controlled trial. Lancet 2012; 379:2449-2458.
6. Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11:171-180.
7. Kilewo C, Karlsson K, Massawe A, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr 2008; 48:315-323.
8. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr 2009; 52:406-416.
9. Marazzi CM, Germano P, Liotta G, et al. Implementing anti-retroviral triple therapy to prevent HIV mother-to-child transmission: a public health approach in resource-limited settings. Eur J Pediatr 2007; 166:1305-1307.
10. Peltier CA, Ndayisaba GF, Lepage P, et al. Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda. AIDS 2009; 23:2415-2423.
11. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362:2282-2294.
12. Taha TE, Li Q, Hoover DR, et al. Postexposure prophylaxis of breastfeeding HIV-exposed infants with antiretroviral drugs to age 14 weeks: updated efficacy results of the PEPI-Malawi trial. J Acquir Immune Defic Syndr 2011; 57:319-325.
13. Thomas TK, Masaba R, Borkowf CB, et al. Tripleantiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding-the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med 2011; 8:e1001015.
14. nd International AIDS Society Conference on HIV Pathogenesis. 13-16 July 2003, Paris, France. Abstract LB07.
15. WHO. The use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a publica health approach. (Updated June 2013. Accessed 19 September 2014.) Available from http://apps.who.int/iris/ bitstream/10665/85321/1/9789241505727-eng.pdf
16. th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, Canada. Abstract 947.
17. th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Poster 648.
18. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009; 53:1170-1176.
19. Schneider S, Peltier A, Gras A, et al. Efavirenz in human breast milk, mothers', and newborns' plasma. J Acquir Immune Defic Syndr 2008; 48:450-454.
20. Shapiro RL, Holland DT, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005; 192:720-727.
21. Palombi L, Pirillo MF, Andreotti M, et al. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther 2012; 17:1511-1519.
22. Rezk NL, White N, Bridges AS, et al. Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications. Ther Drug Monit 2008; 30:611-619.
23. Frontier Science and Technology Rsearc Foundation, Inc. National Institute for Allergy and Infectious Diseases, Division of AIDS. Clinical pharmacology quality assurance antiretroviral proficiency testing program. (Accessed 19 September 2014.) Available from www.fstrf.org
24. KKGT. In association for quality assessment in TDM and clinical toxicology. A section of the Dutch Foundation for quality assessment in medical laboratories. (Accessed 19 September 2014.) Available from www.kkgt.nl
25. Moore KH, Shaw S, Laurent AL, et al. Lamivudine/ zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. J Clin Pharmacol 1999; 39:593-605.
26. Kaletra (lopinavir/ritonavir) Abbott Laboratories, North Chicago, IL, USA Package Insert 2013
27. Kaletra (lopinavir/ritonavir). Package insert 2013. Abbott Laboratories, North Chicago, IL, USA. 27. Veldkamp AI, van Heeswijk RP, Mulder JW, et al. Steadystate pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J Acquir Immune Defic Syndr 2001; 27:344-349.
28. Anderson GD. Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol 2006; 2:947-960.
29. Riant P, Urien S, Albengres E, Duche JC, Tillement JP. High plasma protein binding as a parameter in the selection of betablockers for lactating women. Biochem Pharmacol 1986; 35:4579-4581. Accepted 10 January 2014; published
30. Olagunju A, Owen A, Cressey TR. Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. Pharmacogenomics 2012; 13:1501-1522.
31. Alcorn J, Lu X, Moscow JA, McNamara PJ. Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction. J Pharmacol Exp Ther 2002; 303:487-496.
32. Fiscus S.A. , Aldrovandi G.M.. Virologic determinants of breast milk transmission of HIV-1.Adv Exp Med Biol2012; 743:69-80